These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 1466958)
1. Specific activation strategies for amplification of low CTL signals. Weinhold KJ; Tartaglia J; Paoletti E; Graham B; Schwartz D; McElrath J; Roberts N; Gorse G AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1373. PubMed ID: 1466958 [No Abstract] [Full Text] [Related]
2. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897 [TBL] [Abstract][Full Text] [Related]
3. Cell-mediated immunity: induction and expression of T-cell function. Lawman MJ J Am Vet Med Assoc; 1982 Nov; 181(10):1022-9. PubMed ID: 6294025 [No Abstract] [Full Text] [Related]
4. In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children. McFarland EJ; Harding PA; MaWhinney S; Schooley RT; Kuritzkes DR J Immunol; 1998 Jul; 161(1):513-9. PubMed ID: 9647263 [TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075 [TBL] [Abstract][Full Text] [Related]
6. Assessing the antiviral activity of HIV-1-specific cytotoxic T lymphocytes. Yang OO Methods Mol Biol; 2009; 485():407-15. PubMed ID: 19020840 [TBL] [Abstract][Full Text] [Related]
7. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice. Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. Hanke T; Blanchard TJ; Schneider J; Ogg GS; Tan R; Becker M; Gilbert SC; Hill AV; Smith GL; McMichael A J Gen Virol; 1998 Jan; 79 ( Pt 1)():83-90. PubMed ID: 9460927 [TBL] [Abstract][Full Text] [Related]
9. Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand. Kantakamalakul W; De Souza M; Karnasuta C; Brown A; Gurunathan S; Birx D; Thongcharoen P; Taveg T AIDS Res Hum Retroviruses; 2004 Jun; 20(6):642-4. PubMed ID: 15242541 [TBL] [Abstract][Full Text] [Related]
10. ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses. Mahdavi M; Ebtekar M; Khorram Khorshid HR; Azadmanesh K; Hartoonian C; Hassan ZM Immunol Lett; 2011 Oct; 140(1-2):14-20. PubMed ID: 21679728 [TBL] [Abstract][Full Text] [Related]
11. New strategies to combat HIV: augmenting antiviral immunity. Smith KA; Boyle BA AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321 [No Abstract] [Full Text] [Related]
12. V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells. Lu L; Zhu Y; Diao J; Wang Z; Chen YH Vaccine; 2008 Feb; 26(6):845-52. PubMed ID: 18191003 [TBL] [Abstract][Full Text] [Related]
13. IL-15 stimulates the expansion of AIDS virus-specific CTL. Kanai T; Thomas EK; Yasutomi Y; Letvin NL J Immunol; 1996 Oct; 157(8):3681-7. PubMed ID: 8871670 [TBL] [Abstract][Full Text] [Related]
14. Summary: Clinical Immunology Working Group. Zolla-Pazner S; Mathieson BJ; Walker MC; Walker B AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1441-3. PubMed ID: 1361354 [No Abstract] [Full Text] [Related]
15. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. Yang OO AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558 [No Abstract] [Full Text] [Related]
16. Resistance to viral infection by intraepithelial lymphocytes in HIV-1 P18-I10-specific T-cell receptor transgenic mice. Kuribayashi H; Wakabayashi A; Shimizu M; Kaneko H; Norose Y; Nakagawa Y; Wang J; Kumagai Y; Margulies DH; Takahashi H Biochem Biophys Res Commun; 2004 Apr; 316(2):356-63. PubMed ID: 15020225 [TBL] [Abstract][Full Text] [Related]
17. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Emini EA; Koff WC Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131 [No Abstract] [Full Text] [Related]
18. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. Wagner R; Böltz T; Deml L; Modrow S; Wolf H J Gen Virol; 1993 Jul; 74 ( Pt 7)():1261-9. PubMed ID: 7687647 [TBL] [Abstract][Full Text] [Related]